Citadel Advisors
EGRX

Citadel Advisors’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Citadel Advisors’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-100
Closed -$373 – 15777
2024
Q3 		$373 Buy
+100
New +$477 ﹤0.01% 14033
2024
Q2 		– Sell
-6,000
Closed -$31.4K – 15698
2024
Q1 		$31.4K Buy
6,000
+900
+18% +$4.94K ﹤0.01% 12657
2023
Q4 		$26.7K Buy
5,100
+3,800
+292% +$37.5K ﹤0.01% 12369
2023
Q3 		$20.5K Buy
1,300
+800
+160% +$14.4K ﹤0.01% 12611
2023
Q2 		$9.72K Sell
500
-300
-38% -$7.12K ﹤0.01% 13246
2023
Q1 		$22.7K Buy
800
+300
+60% +$8.91K ﹤0.01% 12974
2022
Q4 		$14.6K Buy
+500
New +$15.9K ﹤0.01% 13385
2022
Q2 		– Sell
-9,800
Closed -$485K – 14387
2022
Q1 		$485K Buy
+9,800
New +$470K ﹤0.01% 9474
2020
Q2 		– Sell
-5,600
Closed -$258K – 10655
2020
Q1 		$258K Sell
5,600
-800
-13% -$40.1K ﹤0.01% 7581
2019
Q4 		$385K Buy
6,400
+800
+14% +$47.7K ﹤0.01% 7214
2019
Q3 		$317K Sell
5,600
-6,100
-52% -$343K ﹤0.01% 7471
2019
Q2 		$651K Buy
11,700
+900
+8% +$46.9K ﹤0.01% 6398
2019
Q1 		$545K Buy
+10,800
New +$481K ﹤0.01% 6648
2018
Q4 		– Sell
-21,300
Closed -$1.48M – 9893
2018
Q3 		$1.48M Buy
21,300
+8,200
+63% +$622K ﹤0.01% 4895
2018
Q2 		$991K Buy
13,100
+900
+7% +$56.6K ﹤0.01% 5234
2018
Q1 		$643K Sell
12,200
-200
-2% -$11.6K ﹤0.01% 5469
2017
Q4 		$662K Buy
12,400
+1,400
+13% +$77.9K ﹤0.01% 5248
2017
Q3 		$656K Buy
11,000
+800
+8% +$48.4K ﹤0.01% 4935
2017
Q2 		$805K Sell
10,200
-17,100
-63% -$1.4M ﹤0.01% 4413
2017
Q1 		$2.26M Buy
27,300
+9,100
+50% +$677K ﹤0.01% 2933
2016
Q4 		$1.44M Sell
18,200
-10,700
-37% -$777K ﹤0.01% 3350
2016
Q3 		$2.02M Sell
28,900
-6,300
-18% -$349K ﹤0.01% 2957
2016
Q2 		$1.36M Buy
35,200
+18,100
+106% +$754K ﹤0.01% 3174
2016
Q1 		$693K Buy
17,100
+13,200
+338% +$838K ﹤0.01% 3956
2015
Q4 		$346K Sell
3,900
-600
-13% -$47.4K ﹤0.01% 5018
2015
Q3 		$333K Buy
4,500
+100
+2% +$8.32K ﹤0.01% 5411
2015
Q2 		$356K Buy
+4,400
New +$287K ﹤0.01% 5492

Other funds holding EGRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
AIC
Archer Investment Corporation Carmel, Indiana $469M AUM 19.1% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Citadel Advisors's EGRX Position: Q4 2024 in Review

Citadel Advisors sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2024, closing a stake of 26,013 shares — an estimated $97K sold.

Citadel Advisors first reported a position in EGRX in Q1 2015 and held it in 37 quarters. The position peaked at $20.7M in Q3 2018. 9 funds tracked by Wall St. Rank hold EGRX as of Q4 2024.

  • Citadel Advisors reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2024 after selling out during the quarter.
  • Citadel Advisors sold 26,013 Eagle Pharmaceuticals, Inc. shares in Q4 2024, an estimated $97K.
  • Citadel Advisors first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2015 and held it in 37 quarters.
  • Citadel Advisors's Eagle Pharmaceuticals, Inc. position peaked at $20.7M in Q3 2018.
  • 9 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2024.

Based on Citadel Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.